Frankfurt
01.04.26 | 08:02
0,093 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.05. | SkinBioTherapeutics - Holding(s) in Company | 2 | RNS | ||
| 05.05. | SkinBioTherapeutics - Holding(s) in Company | 1 | RNS | ||
| 01.05. | OptiBiotix Health - Partial Disposal of Shares in SkinBioTherapeutics | - | RNS | ||
| 29.04. | SkinBioTherapeutics - Update on the FRP Investigation | 1 | RNS | ||
| 01.04. | SkinBioTherapeutics shares suspended on delay to interim results | 1 | Sharecast | ||
| 01.04. | SkinBioTherapeutics - Holding(s) in Company | - | RNS | ||
| SKINBIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.04. | XFRA 5KW: AUSSETZUNG/SUSPENSION | 101 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSKINBIO THERAP LS-... ► Artikel lesen | |
| 01.04. | AIM - Suspension - Skinbiotherapeutics plc | 1 | RNS | ||
| 01.04. | SkinBioTherapeutics - Statement re. Suspension | 1 | RNS | ||
| 20.03. | SkinBioTherapeutics faces April trading suspension until review ends | 1 | Alliance News | ||
| 20.03. | SkinBioTherapeutics faces trading suspension amid probe | 1 | Investing.com | ||
| 20.03. | SkinBioTherapeutics: Handelsaussetzung wegen interner Untersuchung droht | 2 | Investing.com Deutsch | ||
| 20.03. | SkinBioTherapeutics: Update On Board Investigation and Interims Date | - | RNS | ||
| 09.03. | SkinBioTherapeutics adds interim CEO Rachel Parsonage to board | 2 | Alliance News | ||
| 09.03. | SkinBioTherapeutics - Appointment of the Interim CEO to the Board | - | RNS | ||
| 02.03. | AIM Market Roundup: IQE, System1, SkinBioTherapeutics | 3 | The Armchair Trader | ||
| 02.03. | SkinBioTherapeutics appoints interim CEO as investigation continues | 2 | Alliance News | ||
| 02.03. | SkinBioTherapeutics - Appointment of Interim CEO | 1 | RNS | ||
| 20.02. | IN BRIEF: SkinBioTherapeutics board member to oversee external probe | 1 | Alliance News | ||
| 20.02. | Skinbiotherapeutics brings in new audit chair, launches forensic review | 1 | Sharecast |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRAIN BIOTECH | 2,920 | -7,59 % | EQS-AFR: BRAIN Biotech AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: BRAIN Biotech AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
BRAIN Biotech AG: Vorabbekanntmachung über... ► Artikel lesen | |
| MAAT PHARMA | 3,300 | +10,92 % | MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg) in the treatment of acute Graft-versus-Host Disease | During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a "negative trend" opinion for the upcoming June... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,620 | -4,87 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| CG ONCOLOGY | 64,25 | -0,53 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| QIAGEN | 30,290 | +0,65 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,240 | -6,38 % | Tango Therapeutics Shares Fall 17% | ||
| PRAXIS PRECISION MEDICINES | 343,26 | -2,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,640 | +0,18 % | Cogent Biosciences: Aktie legt vor wichtigen Studiendaten um 4 % zu | ||
| GEOVAX LABS | 3,630 | +32,00 % | EQS-News: GeoVax, Inc.: GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms 20.05.2026 / 16:06... ► Artikel lesen | |
| METAVIA | 3,850 | +34,15 % | MetaVia: Präklinische Studie zu Vanoglipel untermauert Potenzial bei Lebererkrankungen | ||
| IMMUNEERING | 5,390 | +3,26 % | Immuneering Corporation: Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | - Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,535 | -0,92 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | -0,90 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| IMMUNOVANT | 34,140 | +0,03 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,640 | +3,51 % | Beam Therapeutics presents AATD gene therapy trial data at ATS |
SKINBIOTHERAPEUTICS PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,093 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SKINBIOTHERAPEUTICS PLC finden Sie auf Wallstreet Online.